Molecular docking studies of potent and selective orally bioavailable dihydro-pyrazole Gpr-40 agonists as Alpha-Glucosidase Inhibitors (AGIS)

The primary goal of this study is to bring the elevated blood sugars down to a normal range, both to improve symptoms of diabetes as well as to prevent or delay diabetic complications. Achieving this goal requires a comprehensive, coordinated, patient-centered approach on the part of the healthcare system. The potions extracted from the generated Docking models are statistically aesthetic and provide enough assumptions about the character as well as the nature of substitutions favourable to boost the biological efficiency of novel analogous. The potion provided by these computational studies helps to derive an impactful path to design more potent antihyperglycemic counterparts of dihydro-pyrazole.